StratifAI is a precision oncology company founded in Berlin that applies artificial intelligence to identify prognostic and predictive biomarkers from multimodal clinical data. Its core product, the Polaris™ platform, fuses H&E histology with RNA-Seq gene expression to link spatial tumor signals directly to patient outcomes, speeding up biomarker discovery while lowering associated costs. The company is assembling a large multimodal reference dataset from collected tumor samples to continually expand its portfolio of spatial biomarkers. StratifAI’s first commercial test, Polaris™ Breast, assesses metastasis risk in early breast cancer and is currently undergoing regulatory review in the EU and the United States. Fresh capital is earmarked to complete clinical validation of Polaris™ Breast and to establish a scalable regulatory framework for clinical AI diagnostics. In parallel, the firm is deepening collaborations with oncology centers and pharmaceutical partners to build the clinical evidence required for guideline inclusion and routine practice. By leveraging growing digital pathology data, StratifAI aims to unlock a sizable, under-served market in cancer diagnostics and deliver more individualized and equitable care for patients with solid tumors.

Total raised

$15M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2025